BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 26032929)

  • 1. Irreversible electroporation for nonthermal tumor ablation in patients with hepatocellular carcinoma: initial clinical experience in Japan.
    Sugimoto K; Moriyasu F; Kobayashi Y; Saito K; Takeuchi H; Ogawa S; Ando M; Sano T; Mori T; Furuichi Y; Nakamura I
    Jpn J Radiol; 2015 Jul; 33(7):424-32. PubMed ID: 26032929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irreversible electroporation of hepatocellular carcinoma: preliminary report on the diagnostic accuracy of magnetic resonance, computer tomography, and contrast-enhanced ultrasound in evaluation of the ablated area.
    Granata V; de Lutio di Castelguidone E; Fusco R; Catalano O; Piccirillo M; Palaia R; Izzo F; Gallipoli AD; Petrillo A
    Radiol Med; 2016 Feb; 121(2):122-31. PubMed ID: 26345332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irreversible Electroporation of Malignant Hepatic Tumors--Alterations in Venous Structures at Subacute Follow-Up and Evolution at Mid-Term Follow-Up.
    Dollinger M; Müller-Wille R; Zeman F; Haimerl M; Niessen C; Beyer LP; Lang SA; Teufel A; Stroszczynski C; Wiggermann P
    PLoS One; 2015; 10(8):e0135773. PubMed ID: 26270651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-center nonrandomized clinical trial to assess the safety and efficacy of irreversible electroporation (IRE) ablation of liver tumors in humans: Short to mid-term results.
    Frühling P; Nilsson A; Duraj F; Haglund U; Norén A
    Eur J Surg Oncol; 2017 Apr; 43(4):751-757. PubMed ID: 28109674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irreversible electroporation for unresectable hepatocellular carcinoma: initial experience and review of safety and outcomes.
    Cheung W; Kavnoudias H; Roberts S; Szkandera B; Kemp W; Thomson KR
    Technol Cancer Res Treat; 2013 Jun; 12(3):233-41. PubMed ID: 23369152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Safety and Efficacy of Irreversible Electroporation for Large Hepatocellular Carcinoma.
    Zeng J; Liu G; Li ZH; Yang Y; Fang G; Li RR; Xu KC; Niu L
    Technol Cancer Res Treat; 2017 Feb; 16(1):120-124. PubMed ID: 27837054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irreversible Electroporation for Unresectable Hepatocellular Carcinoma: Initial Experience.
    Kalra N; Gupta P; Gorsi U; Bhujade H; Chaluvashetty SB; Duseja A; Singh V; Dhiman RK; Chawla YK; Khandelwal N
    Cardiovasc Intervent Radiol; 2019 Apr; 42(4):584-590. PubMed ID: 30697637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multimodality imaging to assess immediate response following irreversible electroporation in patients with malignant hepatic tumors.
    Sugimoto K; Moriyasu F; Saito K; Kobayashi Y; Itoi T
    J Med Ultrason (2001); 2017 Jul; 44(3):247-254. PubMed ID: 27933441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irreversible Electroporation in the Treatment of Hepatocellular Carcinoma.
    Lencioni R; Crocetti L; Narayanan G
    Tech Vasc Interv Radiol; 2015 Sep; 18(3):135-9. PubMed ID: 26365542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse effects of irreversible electroporation of malignant liver tumors under CT fluoroscopic guidance: a single-center experience.
    Dollinger M; Beyer LP; Haimerl M; Niessen C; Jung EM; Zeman F; Stroszczynski C; Wiggermann P
    Diagn Interv Radiol; 2015; 21(6):471-5. PubMed ID: 26359870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a robotic system for irreversible electroporation (IRE) of malignant liver tumors: initial results.
    Beyer LP; Pregler B; Michalik K; Niessen C; Dollinger M; Müller M; Schlitt HJ; Stroszczynski C; Wiggermann P
    Int J Comput Assist Radiol Surg; 2017 May; 12(5):803-809. PubMed ID: 27653615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colorectal liver metastatic disease: efficacy of irreversible electroporation--a single-arm phase II clinical trial (COLDFIRE-2 trial).
    Scheffer HJ; Vroomen LG; Nielsen K; van Tilborg AA; Comans EF; van Kuijk C; van der Meijs BB; van den Bergh J; van den Tol PM; Meijerink MR
    BMC Cancer; 2015 Oct; 15():772. PubMed ID: 26497813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic response assessment of percutaneous radiofrequency ablation for hepatocellular carcinoma: utility of contrast-enhanced agent detection imaging.
    Kim CK; Choi D; Lim HK; Kim SH; Lee WJ; Kim MJ; Lee JY; Jeon YH; Lee J; Lee SJ; Lim JH
    Eur J Radiol; 2005 Oct; 56(1):66-73. PubMed ID: 15913940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Irreversible Electroporation for the Treatment of Hepatocellular Carcinoma Not Amenable to Thermal Ablation Techniques: A Retrospective Single-Center Case Series.
    Sutter O; Calvo J; N'Kontchou G; Nault JC; Ourabia R; Nahon P; Ganne-Carrié N; Bourcier V; Zentar N; Bouhafs F; Sellier N; Diallo A; Seror O
    Radiology; 2017 Sep; 284(3):877-886. PubMed ID: 28453431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Midterm Safety and Efficacy of Irreversible Electroporation of Malignant Liver Tumors Located Close to Major Portal or Hepatic Veins.
    Distelmaier M; Barabasch A; Heil P; Kraemer NA; Isfort P; Keil S; Kuhl CK; Bruners P
    Radiology; 2017 Dec; 285(3):1023-1031. PubMed ID: 28799842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irreversible Electroporation For Hepatocellular Carcinoma: Longer-Term Outcomes At A Single Centre.
    Freeman E; Cheung W; Kavnoudias H; Majeed A; Kemp W; Roberts SK
    Cardiovasc Intervent Radiol; 2021 Feb; 44(2):247-253. PubMed ID: 33051707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of tolerability and efficacy of irreversible electroporation (IRE) in treatment of Child-Pugh B (7/8) hepatocellular carcinoma (HCC).
    Bhutiani N; Philips P; Scoggins CR; McMasters KM; Potts MH; Martin RC
    HPB (Oxford); 2016 Jul; 18(7):593-9. PubMed ID: 27346140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ablation of colorectal liver metastases by irreversible electroporation: results of the COLDFIRE-I ablate-and-resect study.
    Scheffer HJ; Nielsen K; van Tilborg AA; Vieveen JM; Bouwman RA; Kazemier G; Niessen HW; Meijer S; van Kuijk C; van den Tol MP; Meijerink MR
    Eur Radiol; 2014 Oct; 24(10):2467-75. PubMed ID: 24939670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease.
    Ichikawa T; Saito K; Yoshioka N; Tanimoto A; Gokan T; Takehara Y; Kamura T; Gabata T; Murakami T; Ito K; Hirohashi S; Nishie A; Saito Y; Onaya H; Kuwatsuru R; Morimoto A; Ueda K; Kurauchi M; Breuer J
    Invest Radiol; 2010 Mar; 45(3):133-41. PubMed ID: 20098330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bile Duct Injury after Irreversible Electroporation of Hepatic Malignancies: Evaluation of MR Imaging Findings and Laboratory Values.
    Dollinger M; Zeman F; Niessen C; Lang SA; Beyer LP; Müller M; Stroszczynski C; Wiggermann P
    J Vasc Interv Radiol; 2016 Jan; 27(1):96-103. PubMed ID: 26777402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.